title: Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma.
abstract: OBJECTIVE
  It has been suggested that interleukin-6 (IL-6) is a prognostic indicator for survival in patients with gastric carcinoma, but this has not been proved using survival analysis. In Asians, the -634G allele is associated with increased IL-6 production. The objective of this study was to evaluate the association between serum IL-6 levels, -634G/C polymorphism, and overall survival after resection for gastric carcinoma.
  
  
  METHODS
  A total of 155 consecutive patients with gastric carcinoma were evaluated. Serum IL-6 levels were analyzed using an enzyme-linked immunoabsorbent assay. Genotype was determined by PCR and restriction fragment length polymorphism. Serum levels and survival were correlated with genotype and clinicopathologic factors.
  
  
  RESULTS
  Age and stage, but not -634G/C genotype, were associated with serum IL-6 levels. The median survival for patients with stage II or stage III gastric carcinoma was 1,418 days in patients with low (< or =13 pg/mL) versus 618 days in patients with high (>13 pg/mL) serum IL-6 levels (P = 0.038). Results of a multivariate analysis showed that serum IL-6 level of >13 pg/mL was a significant predictor of poor survival (hazard ratio, 1.77; 95% confidence interval, 1.07-2.92; P = 0.026).
  
  
  CONCLUSIONS
  Serum IL-6 level of >13 pg/mL correlates with tumor progression and is an independent predictor of poor survival after resection. In patients with stage II and III gastric carcinoma, serum IL-6 level is more effective than stage as a prognostic indicator. By measuring IL-6, these patients can be divided into two groups with significant differences in survival. The -634G/C polymorphism is not associated with serum IL-6 level or survival.
authors.affiliation: Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
authors.forename: Wei-Chih
authors.initials: WC
authors.lastname: Liao
authors.forename: Jaw-Town
authors.initials: JT
authors.lastname: Lin
authors.forename: Chun-Ying
authors.initials: CY
authors.lastname: Wu
authors.forename: Shih-Pei
authors.initials: SP
authors.lastname: Huang
authors.forename: Ming-Tsan
authors.initials: MT
authors.lastname: Lin
authors.forename: Ariel Sing-Huei
authors.initials: AS
authors.lastname: Wu
authors.forename: Yu-Jie
authors.initials: YJ
authors.lastname: Huang
authors.forename: Ming-Shiang
authors.initials: MS
authors.lastname: Wu
mesh_terms: D000368:Aged; D018450:Disease Progression; D005260:Female; D005838:Genotype; D006801:Humans; D015850:Interleukin-6 / Q000097:blood* / Q000235:genetics; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011110:Polymorphism, Genetic; D013274:Stomach Neoplasms / Q000097:blood* / Q000235:genetics / Q000401:mortality / Q000601:surgery*; D015996:Survival Rate
chemical_list: D015850:Interleukin-6